Device Trial Radar · NCT04358003
Plasma Adsorption in Patients With Confirmed COVID-19
Last checked: Nov 20, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
May 20, 2020
Primary completion
Nov 26, 2021
Study completion Apr 1, 2022
Sponsor
- Lead sponsor
- Marker Therapeutics AGNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Terumo BCT
- First posted
- Apr 22, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.
Conditions
- Respiratory Failure
- ARDS
Interventions
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)Device
Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected. Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortalityTime frame: Day 28
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences (UAMS)
Little Rock, Arkansas
UNM Health Science Center
Albuquerque, New Mexico
Providence Portland Medical Center
Portland, Oregon
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.